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Abstract. The GHRH test and L-dopa test were per-
formed in l2 normal young men (24.1+ I .l years) and l2
normal elderly men (77.8+1.4 years) to investigate age-
related changes in secretion of GHRH, GH and IGF-I.
The basal plasma levels of GHRH and GH were not sig-
nificantly different in young and elderly men, but the
basal plasma level of IGF-I was higher in the young men
( 159.0+ 11.7 vs 86.7+ 11.6 pg/l). The area under the curve
for plasma GH in the GHRH test was less in the elderly
group (35.1+5.9 vs I1.2+2.1 t g.h ' .l-r, p<0.001). The
AUCs for the plasma GHRH and GH responses in the
L-dopa test in young and elderly men were 32.0+2.7 vs
20.3+l.8 rg h-' l-'(p<0.001), and 21.8+4.6 vs
5.4+1.1 pg ' h ' ' l-t (p<0.01), respectively, indicating
decreased releases of GHRH and GH in the elderly. Cor-
relations between the AUCs for plasma GHRH and GH
responses in L-dopa were found in both groups, but the
ratio of the AUCs for GH/GHRH was lower in the elderly
group. The elderly group showed a significant correla-
tion between the basal plasma IGF-I level and the AUCs
for plasma GH in the GHRH and L-dopa tests. These
results suggest that elderly men have a decreased reserve
of hypothalamic GHRH, resulting in secondarily im-
paired GH release, which may lead to a lower level of
IGF-I than in young men.
The age-related change in GH secretion in men is
still controversial: the basal GH concenrations in
elderly men have been reported to be either un-
changed (l) or decreased (2). However, spontane-
ous 24-h secretion of GH in human subjects is re-
ported to decrease with age (2,3). With regard to
the plasma GH response to exogenous GHRH in
the elderly, Shibasaki et al. (4) and Lang et al. (5)
reported a marked decrease in men older than 40
years, but Pavlov et al. (6) observed no age-related
decrease in the GH response to GHRH even in
subjects in their eighties.
The development of a radioimmunoassay for
plasma GHRH enabled us to evaluate hypotha-
lamic-pituitary function by measuring plasma
GHRH and GH in normal subjects and patients
with various endocrine disorders (7). We have re-
ported an increase in plasma GHRH after oral ad-
ministration of L-dopa followed by GH release (8).
These findings \{'ere confirmed by others (9-11).
In the present study, we compared the function
of the GHRH-GH axis in young and elderly men by
measuring the plasma GH response to GHRH and
the plasma GHRH and GH responses to L-dopa, in
addition to the basal plasma IGF-I level.
Subjects and Methods
Subjech and protocok
The subjects studied consisted of I 2 young and I 2 elderly
males with no obesity or endocrine disorder (Table l).
The study was approved by the Human Subjects Protec-
tion Committee, School of Medicine, University of To-
kushima, and informed consent was obtained from all
subjects participating in the study.
Tests were performed on subjects in bed after over-
night fasting. At least 30 min before the start of each test,
a 2l-gauge indwelling needle was inserted into the ante-
cubital vein and blood samples were taken serially
through a cannula before and after administration of
GHRH or L-dopa.
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Table l.
Age, body mass index (BMI), area under the curve (AUC) for plasma GHRH and GH in the L-dopa test, AUC for
plasma GH in the GHRH test, and basal plasma IGF-I levels in young and elderly men.
Case
No.
Ag.
(years;
BⅣII
(kg7 m2)
L-dopa test GHRH testbasal IGF I
GHRH
(ng・h~1
1~1)
GH
(μg・h~1
1~1)
GH
(μg h~1
1~1)
Young 1
2
3
4
5
6
7
8
9
10
11
12
25
24
31
23
24
27
21
20
20
23
21
30
243
179
210
223
179
225
237
178
168
180
216
211
372
412
294
347
397
310
259
535
217
229
255
213
227
212
185
315
120
181
331
570
89
93
161
13 1
611
418
250
174
252
494
55.1
68.9
377
95
155
147
2115
1910
1865
1657
1757
1597
1702
1453
1275
1005
787
1957
Mean
tsnr
241
11
204
15
320
27
218
46
351
59
1590
H7
Eldcriv 201
186
238
197
232
204
200
210
203
194
225
196
146
224
282
123
253
204
263
20.7
109
152
19.5
277
72
78
110
14
17
40
96
30
16
09
52
105
197
14.9
12.8
92
42
137
153
22
0.8
17.4
28
211
1018
49.3
911
831
344
1128
1305
756
469
563
851
1729
1
2
3
4
5
6
7
8
9
10
11
12
74
81
77
78
79
70
84
81
80
73
85
71
Mean
tsru
778
14
207
09
203
18
54
11
112
21
867
116
GHRH and L-dopa tests
A svnthetic preparation of GHRH(l-44)NH, (100 pg, Su-
mitomo Pharmaceutical Co, Ltd, Osaka, Japan), which is
a registered drug for hormonal examination, were ad-
ministered iv. Blood samples were obtained serially 0, 15,
30, 45, 60, 90 and 120 min after GHRH administration,
and the plasma concentrations of GH were measured.
A dose of 500 mg of L-dopa was administered orally,
and serial blood samples were obtained 0, 30, 60, 90 and
120 min later for measuring the plasma concentrations of
GHRH and GH.
Radioimmunoassals of plasma GHRH, GH and IGF-I
GHRH was extracted from plasma as described previ-
ously (7,1 l). Briefly, 3.5 ml of plasma was mixed with 7 ml
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of cold acetic acid-acetone solution (3:100, vol/vol) and
centrifuged. The supernatant was extracted twice with 20
ml of petroleum ether, and the ether layer was carefully
removed. Remaining acetone was eliminated by evapora-
tion, and the aqueous portion was lyophilized. The resi-
due was dissolved in assay buffer and subjected to RIA for
GHRH.
Synthetic GHRH(l-44)NH, (generously provided by
Dr A. Felix, Hoffman-La Roche Inc, Nutley, NJ) was la-
belled with r25I by the chloramine-T method and the
iodinated product rvas purified on a I x 10 cm carboxy-
methyl cellulose column (CM 23, Whatman, Maidstone,
England). The anti-GHRH serum (RAS-8061, Peninsula
Lab, San Carlos, CA; lot No. 004118) used in this study
did not cross-react with relevant neuropeptides and rec-
ognized the N-terminal and part of the middle portion of
the amino acid sequence of GHRH(1-44)NHr. When syn-
thetic GHRH(l-44)NH2 was used as standard, the sensi-
tivity of this assay was 4 pg/tube. As the extract from I ml
of plasma was dissolved in I 00 pl of assay buffer and used
for the assay as well as 100 pl of the standard, the least
detectable value was 4 ng/I. Antibody-bound and free
tracers were separated by the double-antibody method.
The recovery of 30 pg of synthetic GHRH(1-44)NH,
added to 1 ml of plasma was 59.5+2.lVo. The intra- and
inter-assay coefficients of variation were less than 10%.
The plasma GH concentration was measured with a
radioimmunoassay kit, HGH-II (Dianabot Co, Ltd.,
Tokyo, Japan). The sensitivity of the assay \r'as 0.3 pg/1,
and the intra- and inter-assay coefficients of variation
were 5.7 -6.3Vo and, 3.4-5.6%, respectively.
We have previously reported the basal plasma IGF-I
level measured by radioimmunoassay ( l2). A biosynthetic
homologue of IGF-I and its specific antiserum were
kindly provided by Fujisawa Pharmaceutical Co, Ltd,
Osaka,Japan. The antiserum recognizes three portions of
the IGF-I molecule: the N-terminal portion (the first five
amino acid residues), middle portions (residues l3 to 20
and 2l to 33), and C-terminal portions (residues 47 to 53
and 60 to 70) (13). For RIA, this specific antiserum was
used at a final dilution of l:35 000. Acid-ethanol extrac-
tion of plasma was performed by a slight modification of
the method of Daughaday et al. (14) for removal of the
bulk of plasma proteins, especially the specific binding
protein for IGF-I. The lower limit of detectability of
IGF-I with 95% confidence was 1.5 pgfl, and the intra-
and inter-assay coefficients of variation were less than
llVa.
Statistical analysis
Data are expressed as means tsrru. In calculating mean
values and incremental rises, undetectable plasma hor-
mone levels were assigned a value of the detection limit of
the assay. Student's t-test was used to compare hormone
levels in the two age groups and analysis of variance was
used to compare difference at different time points.
Results
Basal leaels of plasma GHRH, GH and IGF-I in
young and eldtrly men
The plasma concentrations of GHRH, GH and
IGF-I were 9.5+l.l ng/I, 1.0+0.2 and 159.0+11.7
pg/I, respectively, in young men, and 8.3+0.7 ng/I,
0.9+0.2 and 86.7+ 1 1.6 prg/l, respectively, in elderly
men. Only the difference between the basal plasma
IGF-I levels of the two groups was significantly dif-
ferent (p<0.001).
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Fig. t.
Plasma GHRH and/or GH responses to GHRH or L-dopa
in young and elderly men.
a: Plasma GH response to GHRH.
b: Basal and peak plasma GH levels during the GHRH
test.
c: Plasma GHRH response to L-dopa.
d: Basal and peak plasma GHRH levels during the
L-dopa test.
e: Plasma GH response to L-dopa.
f: Basal and peak plasma GH levels during the L-dopa
test.
Points and bars are means and sru for 12 determinations.
*p<0.05 and **p<0.01 vs basal value.
?
?
?
）
??
??
?
?
?
?
ゅ?
〓?
??
?
?
?
?
?
）
????
??
?
?
?
?
?
?
）
?
?
?
?
?
?
?
??
。
?
?
?
?
?
?
?
?
?
?
?
?
??
??
??
?
?
(c)
33
,:ff-" GH response to GHRH in loung and elderll
Both the young and elderly men showed a rise in
plasma GH level in response to GHRH, but the
elderly men showed a significantly lower peak
value (29.4+4.2 vs 10.7!2.1 pg/I, p<0.001, Fig. la
and lb).
Plasma GHRH and, GH resporues to L-dopa in young
and elderll men
The plasma GHRH responses to L-dopa in the
young and elderly men are shown in Fig. lc and ld.
The young men showed a higher rise in plasma
GHRH level than the elderly men, the peak GH
levels in the two groups being 22.8+2.5 and
13.5+ 1.5 ngA, respectively (p<0.005).
The plasma GH responses to L-dopa in the two
groups are shown in Fig. te and lf. A rise in plasma
GH level was observed in both groups, but the peak
value was significantly lower in the elderly men
(25.7+9.2 vs 6.0+2.6 pg/I, p<0.001).
Fig. 2 show the correlations between the area
under the curve (AUC) for plasma GHRH and
plasma GH concentrations in the L-dopa test in the
young and the elderly men (r:0.71, p<0.01 and
r=0.69, p<0.05, respectively).
AUC for plasma GHRH (ns'h 'I ) AUC for plasma GHRH (ng'h '' l )
Fig. 2.
Correlation between area under the curve (AUC) for
plasma GHRH and GH in the L-dopa test in young and
elderly men.
a: A significant correlation
(y=-10.1+0.99x, r:0.71, p<0.01) was observed in the
young men.
b: A significant correlation
(y:-3.59+0.44x, r:0.69, p<0.05) was observed in the
elderly men.
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Fig.3.
Correlations between the basal plasma IGF-I level and
AUC for plasma GH in the GHRH and L-dopa tests in
young and elderly men.
a: No significant correlation (r:0.34) was observed
during the GHRH test in the young men.
b: A significant correlation
(y:1.99+0.llx, r=0.58, p<0.05) was observed during
the GHRH test in the elderly men.
c: No significant correlation (r:0.13) was observed dur-
ing the L-dopa test in the young men.
d: A significant correlation
(y:0.12+0.063x, r:0.66, p<0.05) was observed during
the L-dopa test in the elderly men.
Correlatiorx between basal plasma IGF-I leuek and
AUCs for plasma GH in the GHRH and L-d,opa tests
The correlations between the basal plasma IGF-I
levels and AUC of plasma GH in the GHRH test in
young and elderly men are shown in Fig. 3a and 3b-
No correlation was observed in the young men, but
a significant correlation (r:0.58, p<0.05) was
found in the elderly men.
The correlations between the basal plasma IGF-I
levels and AUC for plasma GH in the L-dopa test
in young and elderly men are shown in Fig. 3c and
3d. A significant correlation was found only in the
elderly men (r:0.66, p<0.05).
Discussion
In this work we observed an age-related change in
the plasma GH response to GHRH. This result is
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compatible with those of Shibasaki et al. (4) and
Lang et al. (5), who studied 37 men aged 20-75
years, and 63 men aged 18-95 years old, respec-
tively, but contrasts the report ofPavlov et al. (6) of
no age-dependent alteration in healthy men.
Wealso found that the basal plasma IGF-I levels
were lower in elderly men. This finding is consis-
tent with a report by Florini et al. (15) of decrease
in the basal plasma IGF-I level in elderly men and
a positive correlation between the basal plasma
IGF-I level and, 24-h integrated GH level.
There are reports (7-10) of a GHRH-like sub-
stance that seems to be immunologically indistin-
guishable from synthetic GHRH(l-44)NH, in the
plasma of patients with idiopathic pituitary dwarf-
ism and acromegaly.
The source of plasma GHRH is uncertain, but
the following observations suggest that the GHRH
level in the peripheral blood reflects release of
GHRH from the hypothalamus into the hypophy-
seal-portal vein and results in GH release from the
pituitary. In humans, GHRH is mainly located in
the hypothalamus and pituitary stalk, with only
very small amounts in other organs, including the
digestive tract, pancreas and adrenal gland (4). As
reported earlier, episodic release of GHRH into
the peripheral blood can be detected before or in
association with the GH surge during slow-wave
sleep (8). In addition, oral administration of
L-dopa has been shown to stimulate the releases of
GHRH and GH in normal subjects (8-10), but not
in patients with hypothalamic disorders (10).
We also found significant differences between
young and elderly men in the peak value of plasma
GHRH, the increment of plasma GHRH concen-
tration, and the AUC for plasma GHRH in the
L-dopa test. These results suggest that GHRH se-
cretion from the hypothalamus is impaired in eld-
erly men, and may result in decreased secretions of
GH and IGF-I. In fact, Leppaluoto et al. (16) re-
ported that in young adult men GH release in-
duced by heat exposure is mediated by GHRH, and
that similar responses of GHRH and GH do not
occur in older men. Our results are consistent with
the finding of Leppaluoto et al. (16) that the
GHRH response is impaired in elderly men. In this
connection it is noteworthy that Iovino et al. (17)
reported that repetitive GHRH administration re-
stored the attenuated GH response in the GHRH
test in elderly men.
In the L-dopa test, a positive correlation between
the AUC for GHRH and AUC for GH was found
in elderly men, indicating preserved function of
the GHRH-GH axis. However, the fact that the
slope of the correlation of the AUC for plasma GH
with the AUC for plasma GHRH was lower in the
elderly men also suggested that the capacity to se-
crete GH in response to endogeneous GHRH is
decreased in elderly men.
GH secretion is also regulated by somatostatin
released from the hypothalamus (18,19), and the
somatostatin level is thought to increase with age
(4). The secretory profile of somatostatin from the
hypothalamus cannot be measured, so we cannot
evaluate the participation of somatostatin in the re-
lease of GH during the GHRH and L-dopa tests.
Thus, the possible involvement of somatostatin in
the impaired GH release in elderly men cannot be
excluded.
In this work we found that elderly men showed
a lower GH response to GHRH, and lower GHRH
and GH responses to L-dopa than young men. We
also observed a significant correlation between the
basal plasma IGF-I levels and AUC values for
plasma GH in the GHRH and L-dopa tests. These
results suggest that the function of the hypothala-
mus is decreased in elderly men, resulting in de-
creased releases of GH and IGF-I.
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